| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mei Ji, Xi-Xiu Xie, Dong-Qun Liu, Xiao-Lin Yu, Yue Zhang, Ling-Xiao Zhang, Shao-Wei Wang, Ya-Ru Huang, Rui-Tian Li. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia. Alzheimer's research & therapy. vol 10. issue 1. 2019-08-02. PMID:29914543. |
truncated mis-disordered tau protein plays an important role in the pathogenesis of alzheimer's disease (ad) and frontotemporal dementia (ftd). |
2019-08-02 |
2023-08-13 |
mouse |
| Tommaso Schirinzi, Giulia Di Lazzaro, Vito Luigi Colona, Paola Imbriani, Mohammad Alwardat, Giulia Maria Sancesario, Alessandro Martorana, Antonio Pisan. Assessment of serum uric acid as risk factor for tauopathies. Journal of neural transmission (Vienna, Austria : 1996). vol 124. issue 9. 2019-07-29. PMID:28620833. |
the mean serum ua concentrations of 111 patients with tauopathies (tau), including 41 with progressive supranuclear palsy (psp), 45 with alzheimer's disease (ad) and 25 with frontotemporal dementia (ftd) were compared to that of 130 controls (ctl). |
2019-07-29 |
2023-08-13 |
human |
| Pranav Vemula, Yu Jing, Hu Zhang, Jerry B Hunt, Leslie A Sandusky-Beltran, Daniel C Lee, Ping Li. Altered brain arginine metabolism in a mouse model of tauopathy. Amino acids. vol 51. issue 3. 2019-07-24. PMID:30604097. |
tauopathies consist of intracellular accumulation of hyperphosphorylated and aggregated microtubule protein tau, which remains a histopathological feature of alzheimer's disease (ad) and frontotemporal dementia. |
2019-07-24 |
2023-08-13 |
mouse |
| Kristen M Craven, William R Kochen, Carlos M Hernandez, Jane M Flin. Zinc Exacerbates Tau Pathology in a Tau Mouse Model. Journal of Alzheimer's disease : JAD. vol 64. issue 2. 2019-07-15. PMID:29914030. |
hyperphosphorylated tau protein is a key pathology in alzheimer's disease (ad), frontotemporal dementia, chronic traumatic encephalopathy, and parkinson's disease. |
2019-07-15 |
2023-08-13 |
mouse |
| Amelia Sedjahtera, Lydia Gunawan, Lisa Bray, Lin Wai Hung, Jack Parsons, Nobuyuki Okamura, Victor L Villemagne, Kazuhiko Yanai, Xiang M Liu, Jacky Chan, Ashley I Bush, David I Finkelstein, Kevin J Barnham, Robert A Cherny, Paul A Adlar. Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics : integrated biometal science. vol 10. issue 9. 2019-07-15. PMID:30168573. |
this highlights the potential utility of targeting metal ions as a novel therapeutic strategy for diseases in which tau pathology is a feature, which includes conditions such as frontotemporal dementia and alzheimer's disease. |
2019-07-15 |
2023-08-13 |
mouse |
| Tirth K Patel, LeMoyne Habimana-Griffin, Xuefeng Gao, Baogang Xu, Samuel Achilefu, Kari Alitalo, Celia A McKee, Patrick W Sheehan, Erik S Musiek, Chengjie Xiong, Dean Coble, David M Holtzma. Dural lymphatics regulate clearance of extracellular tau from the CNS. Molecular neurodegeneration. vol 14. issue 1. 2019-07-05. PMID:30813965. |
aside from its role in ad, tau is also involved in several other neurodegenerative disorders collectively called tauopathies, such as progressive supranuclear palsy (psp), corticobasal degeneration (cbd), some forms of frontotemporal dementia, and argyrophilic grain disease (agd). |
2019-07-05 |
2023-08-13 |
Not clear |
| Aurélien Lathuilière, Pamela Valdés, Stéphanie Papin, Matthias Cacquevel, Catherine Maclachlan, Graham W Knott, Andreas Muhs, Paolo Paganetti, Bernard L Schneide. Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects. Scientific reports. vol 7. issue 1. 2019-07-02. PMID:29051562. |
tau pathology is associated with cognitive decline in alzheimer's disease, and missense tau mutations cause frontotemporal dementia. |
2019-07-02 |
2023-08-13 |
mouse |
| Aurélien Lathuilière, Pamela Valdés, Stéphanie Papin, Matthias Cacquevel, Catherine Maclachlan, Graham W Knott, Andreas Muhs, Paolo Paganetti, Bernard L Schneide. Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects. Scientific reports. vol 7. issue 1. 2019-07-02. PMID:29051562. |
the p301s mutation linked to frontotemporal dementia causes tau aggregation and rapidly progressing motor deficits. |
2019-07-02 |
2023-08-13 |
mouse |
| Michel Goeder. Tau filaments in neurodegenerative diseases. FEBS letters. vol 592. issue 14. 2019-06-24. PMID:29790176. |
twenty years ago, we and others showed that mutations in mapt, the tau gene, cause familial forms of frontotemporal dementia, thus proving that dysfunction of tau protein is sufficient to cause neurodegeneration and dementia. |
2019-06-24 |
2023-08-13 |
human |
| Alejandra D Alonso, Leah S Cohe. Our Tau Tales from Normal to Pathological Behavior. Journal of Alzheimer's disease : JAD. vol 64. issue s1. 2019-06-11. PMID:29614672. |
mutations on tau associated with disease, e.g., r406w in frontotemporal dementia with parkinsonism linked to chromosome 17, altered its conformation to make it a better substrate for kinases. |
2019-06-11 |
2023-08-13 |
human |
| Haitham Amal, Guanyu Gong, Elizabeta Gjoneska, Sarah M Lewis, John S Wishnok, Li-Huei Tsai, Steven R Tannenbau. S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy. Translational psychiatry. vol 9. issue 1. 2019-06-10. PMID:30696811. |
mutations in the mapt gene, which encodes the tau protein, are associated with several neurodegenerative diseases, including frontotemporal dementia (ftd), dementia with epilepsy, and other types of dementia. |
2019-06-10 |
2023-08-13 |
mouse |
| Sumihiro Maeda, Yuhei Sato, Akihiko Takashim. Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. Neurobiology of aging. vol 69. 2019-05-21. PMID:29852407. |
frontotemporal dementia with parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. |
2019-05-21 |
2023-08-13 |
mouse |
| Sumihiro Maeda, Yuhei Sato, Akihiko Takashim. Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. Neurobiology of aging. vol 69. 2019-05-21. PMID:29852407. |
the p301 l mutation in tau, a microtubule-associated protein, causes frontotemporal dementia with parkinsonism linked to chromosome-17 (ftdp-17) that is accompanied by formation of filamentous polymers of tau. |
2019-05-21 |
2023-08-13 |
mouse |
| Shieh-Yueh Yang, Ming-Jang Chiu, Ta-Fu Chen, Chin-Hsien Lin, Jiann-Shing Jeng, Sung-Chun Tang, Yen-Fu Lee, Che-Chuan Yang, Bing-Hsien Liu, Hsin-Hsien Chen, Chau-Chung W. Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Scientific reports. vol 7. issue 1. 2019-04-17. PMID:28839167. |
the ultra-sensitive imr assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as alzheimer's disease (ad), mild cognitive impairment (mci) due to ad, parkinson's disease (pd), frontotemporal dementia (ftd) and vascular dementia (vd). |
2019-04-17 |
2023-08-13 |
human |
| Y Akwa, E Gondard, A Mann, E Capetillo-Zarate, E Alberdi, C Matute, S Marty, T Vaccari, A M Lozano, E E Baulieu, D Tampellin. Synaptic activity protects against AD and FTD-like pathology via autophagic-lysosomal degradation. Molecular psychiatry. vol 23. issue 6. 2019-03-18. PMID:28696431. |
in this study, we investigated the effect of synaptic stimulation on tau pathology and synapses in in vivo and in vitro models of ad and frontotemporal dementia (ftd). |
2019-03-18 |
2023-08-13 |
Not clear |
| Victor Tapias, Shari Jainuddin, Manuj Ahuja, Cliona Stack, Ceyhan Elipenahli, Julie Vignisse, Meri Gerges, Natalia Starkova, Hui Xu, Anatoly A Starkov, Lucien Bettendorff, Dmitry M Hushpulian, Natalya A Smirnova, Irina G Gazaryan, Navneet A Kaidery, Sushama Wakade, Noel Y Calingasan, Bobby Thomas, Gary E Gibson, Magali Dumont, M Flint Bea. Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Human molecular genetics. vol 27. issue 16. 2019-03-08. PMID:29860433. |
these findings demonstrate that bft activates the nrf2/are pathway and is a promising therapeutic agent for the treatment of diseases with tau pathology, such as ad, frontotemporal dementia and progressive supranuclear palsy. |
2019-03-08 |
2023-08-13 |
mouse |
| Farah H Bardai, Liqun Wang, Yamini Mutreja, Mythili Yenjerla, T Chris Gamblin, Mel B Fean. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 38. issue 1. 2019-02-21. PMID:29138281. |
a conserved cytoskeletal signaling cascade mediates neurotoxicity of ftdp-17 tau mutations the microtubule binding protein tau is strongly implicated in multiple neurodegenerative disorders, including frontotemporal dementia and parkinsonism linked to chromosome 17 (ftdp-17), which is caused by mutations in tau. |
2019-02-21 |
2023-08-13 |
Not clear |
| Thomas Briston, Amy R Hick. Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention. Biochemical Society transactions. vol 46. issue 4. 2019-02-18. PMID:29986938. |
oligomerisation of aβ, tau, α-synuclein and tdp-43 leads to a toxin gain- or loss-of-function contributing to the phenotype observed in alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis and frontotemporal dementia. |
2019-02-18 |
2023-08-13 |
Not clear |
| Brianne A Kent, Christopher J Heath, Chi Hun Kim, Rosemary Ahrens, Paul E Fraser, Peter St George-Hyslop, Timothy J Bussey, Lisa M Saksid. Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17 months of age. Brain and behavior. vol 8. issue 1. 2019-02-12. PMID:29568692. |
tau is a microtubule-associated binding protein implicated in neurodegenerative tauopathies, including frontotemporal dementia (ftd) and alzheimer's disease (ad). |
2019-02-12 |
2023-08-13 |
mouse |
| B Borroni, J Stanic, C Verpelli, M Mellone, E Bonomi, A Alberici, P Bernasconi, L Culotta, E Zianni, S Archetti, M Manes, S Gazzina, R Ghidoni, L Benussi, C Stuani, M Di Luca, C Sala, E Buratti, A Padovani, F Gardon. Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target. Scientific reports. vol 7. issue 1. 2019-02-11. PMID:28751743. |
frontotemporal dementia (ftd) is a neurodegenerative disorder mainly characterised by tau or tdp43 inclusions. |
2019-02-11 |
2023-08-13 |
human |